SCHEMBL16626659

SCHEMBL16626659

COc1ccc(Nc2ccc3c(CN(C)C(=O)OC(C)(C)C)cn(S(=O)(=O)c4cccc(C(F)(F)F)c4)c3c2)c(Cl)n1

nearest known ligand 0.37

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
RORC P51449 16/20 0.37
SLC20A2 Q08357 1/20 0.36
SLC20A1 Q8WUM9 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16619006 0.92 RORC (0.40) RORCSLC20A2SLC20A1HDAC1HDAC2
SCHEMBL16618638 0.90 HTR6 (0.42) RORCSLC20A2SLC20A1HDAC1HDAC2
SCHEMBL16626662 0.86 RORC (0.37) RORCHDAC1HDAC2HDAC6CYP3A4
SCHEMBL16626748 0.84 RORC (0.38) RORCSLC20A2SLC20A1
Hydrochloric Acid SCHEMBL16618931 0.84 RORC (0.38) RORCSLC20A2SLC20A1
SCHEMBL19971369 0.84 RORC (0.39) RORCSLC20A2SLC20A1CYP3A4CYP2D6
SCHEMBL16619379 0.83 RORC (0.37) RORCSLC20A2SLC20A1
SCHEMBL16619023 0.83 HDAC1 (0.43) RORCSLC20A2SLC20A1HDAC1HDAC2
SCHEMBL16619007 0.82 HTR6 (0.42)
SCHEMBL16618751 0.81 SLC20A2 (0.43) RORCSLC20A2SLC20A1HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI RORC 1067/4885SLC20A2 2810/4885SLC20A1 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.